
Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.
- NVS is trading near recent highs. Track the action here

Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.